We report a patient with human T-cell lymphotropic virus type I (HTLV-I) infection, who presented with proximal extremity neurogenic muscular weakness followed by fulminant myelopathy, but with no upper motor symptoms. The symptoms were inconsistent with the World Health Organization or El Escorial criteria for HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) or amyotrophic lateral sclerosis (ALS). This case indicates that fulminant myelopathy without upper motor neuronal symptoms may occur long after the onset of HTLV-I-associated neurogenic proximal muscular weakness. Additionally, we report that treatment with high-dose steroid pulse therapy partially improves symptoms of lightning pain and sensory disturbance.
Introduction
Human T-cell lymphotropic virus type I (HTLV-I) is associated with various systemic diseases like adult T-cell leukemia/lymphoma (ATL) (1), HTLV-I-associated myelopathy/ tropical spastic paraparesis (HAM/TSP) (2, 3), bronchopneumopathy (4), polyarthritis (5) , and inflammatory myopathy (6, 7) . HTLV-I carriers present with severe muscular atrophy, fasciculation, and pyramidal tract damage similar to those noted in amyotrophic lateral sclerosis (ALS) (8) (9) (10) (11) . Silva et al (12) reported that 1.9% of HTLV-I carriers with neurological symptoms present with an ALS-like syndrome, which is unusual in typical HAM/TSP.
Although magnetic resonance imaging (MRI) scans reveal atrophic changes of the spinal cord in most HAM/TSP patients, several other spinal cord abnormalities may also occur (13) (14) (15) . We previously reported 3 HAM cases wherein the patients exhibited abnormal spinal MRI findings that seemed to reflect active inflammation in the early stages of rapidly progressive HAM (16) .
Here, we present a patient with HTLV-I infection who manifested with neurogenic muscular weakness in the proximal extremities followed by fulminant myelopathy; spinal MRI revealed high-intensity lesions, mainly localized in the posterior horns of the spinal cord, from the cervical to the thoracic level. The clinical features were not necessarily consistent with those of HAM/TSP or ALS, as per the World Health Organization criteria or the El Escorial criteria, because of lack of upper motor neuron symptoms. This case shows that fulminant myelopathy without upper motor neuron symptoms can occur 7 years after the onset of HTLV-I infection-associated neurogenic proximal muscular weakness. Nerve conduction studies demonstrated decreased amplitudes of compound muscle action potential (CMAP) without conduction block in the right median nerve. Needle electromyography revealed widespread giant and polyphasic motor unit potentials without fibrillation or positive sharp waves in the cervical, thoracic, and lumbosacral regions. Analysis of a biopsy of the left biceps brachii muscle ( Fig. 1A) showed neurogenic atrophy, small angulated fibers, and small group atrophy. ATPase staining (Fig. 1B-D) ) revealed the fiber type grouping: most atrophic fibers were type 2 dominant, and the hypertrophic fibers, type 1 dominant. These results suggested the involvement of a chronic neurogenic process. Neither infiltration of inflammatory cells nor necrosis was seen. Cranial and spinal MRI ( Fig. 2A , E, and I), abdominal ultrasonography, gastric fiberscopy, colon fiberscopy, wholebody computed tomography (CT), and gallium scintigraphy provided no evidence of malignancy. With the informed consent of the patient, peripheral blood samples were collected and genomic DNA was extracted; the androgen receptor and survival motor neuron genes were analyzed in these samples by using polymerase chain reaction followed by direct DNA sequencing. However, automated DNA sequencing revealed no genetic mutation or elongation. Thereafter, the patient's symptoms remained without disease progression. Twenty-seven months after the first admission, the patient developed a piercing pain in his left toes, followed by a similar pain in the contralateral toe. The pain radiated to the back and became a lightning pain. One month before the second admission, he developed a paraparesis and was bedridden. On his second admission, a physical examination revealed no superficial lymphadenopathy. Muscle strength in all limbs, particularly the lower extremities, was severely affected, with proximal muscle wasting. Manual muscle testing showed 3/5 in the bilateral upper proximal muscles and 2/5 in the bilateral lower proximal muscles. Deep sensations, including positional and vibration sensations, were severely disturbed in the lower limbs, and to a lesser extent, in the upper limbs. Tactile and pain sensations were mildly affected, and he complained of paresthesia such that a slight touch evoked abnormal pain sensation. Lhermitte's sign was positive. Tendon reflexes were decreased in the upper and lower extremities, but neither Babinski nor Chaddock signs were present. The patient experienced severe constipation and urinary disturbance. The laboratory data are shown in Table 1 . Anti-HTLV-I antibodies were detected in the serum and CSF. We did not measure the HTLV-1 proviral DNA load. CSF analysis revealed increased protein content (56.3 mg/dL) and an IgG level of 5.18 mg/dL. The cell count of the CSF was elevated (31/mm 3 ). Serum anti-nuclear and anti-DNA antibodies, myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA), proteinase-3 antineutrophil cytoplasmic antibody (PR3-ANCA), anti-SS-A/Ro antibody, anti-SS-B/La antibody, anti-Scl-70 antibody, and antiaquaporin 4 antibody were all negative. Nerve conduction studies demonstrated decreased amplitudes of CMAP in the right peroneal nerve and a reduction in the frequency of Fwave production. T2-weighted spinal MRI showed highintensity patchy lesions along the spinal cord, from the cervical to the thoracic level (Fig. 2B, F , and J). Brain MRI showed no remarkable abnormalities. Whole-body CT and gallium scintigraphy did not reveal any findings indicative of lymphoma; however, the soluble interleukin-2 receptor level was elevated. With high-dose steroid pulse treatment of methylprednisolone (1,000 mg/day for 3 days) followed by oral prednisolone (60 mg/day), his symptoms gradually improved. However, follow-up T2-weighted spinal MRI demonstrated high-intensity lesions localized in the posterior horns of the spinal cord, from the cervical to the thoracic level (Fig. 2C, G, and K) . The vitamin B12 and homocyste- ine levels were 232 pg/mL (normal range: 180-914 pg/mL) and 11.2 nmol/L (normal range: 3.7-13.5 nmol/L), respectively. The patient's serum tested negative for syphilis.
Two weeks later, the abnormal sensation and lightning pain in the lower extremities worsened and the patient was prescribed a second course of high-dose methylprednisolone (1,000 mg/day for 3 days) followed by oral prednisolone (60 mg/day). T2-weighted spinal MRI performed during follow-up 2 weeks later showed the spinal cord to be almost normal (Fig. 2D, H, and L) . CSF analysis at follow-up examination showed a decreased cell count (10/mm 3 ) but elevated protein content (63.8 mg/dL). The level of the soluble interleukin-2 receptor was decreased (1,082 U/mL). The patient was transferred to another hospital, where treatment was continued, and the abnormal sensation and lightning pain in the lower extremities gradually improved.
Discussion
On first admission to our hospital, the present patient exhibited neurogenic muscular weakness in the proximal extremities, lasting for at least 5 years. One month before the second admission (27 months later), he developed a paraparesis resulting in a bedridden state. CSF analysis revealed increased cell count, protein content, and IgG level and the presence of anti-HTLV-I antibody. Spinal MRI demonstrated high-intensity lesions mainly localized in the posterior horns of the spinal cord, from the cervical to the thoracic level. On the basis of data obtained from physical examination and laboratory tests, we ruled out the diagnoses of spinal tumor, cervical or thoracic spondylosis, multiple sclerosis, neuromyelitis optica, collagen vascular disease-related myelitis, neurosyphilis, and vitamin B12 deficiency.
HTLV-I has various neurological manifestations such as HAM/TSP, peripheral neuropathy, and inflammatory myopa-thy. Few studies have described an HTLV-I-associated ALSlike syndrome (8) (9) (10) (11) . Matsuzaki et al (10) reported that similar to typical HAM/TSP patients, 5 of 15 patients with the ALS-like syndrome had a higher proviral load in the peripheral blood mononuclear cells; therefore, they concluded that HTLV-I infection could manifest as an ALS-like syndrome. The clinical features of the present patient were not consistent with those of HAM/TSP or ALS, as per the World Health Organization criteria or the El Escorial criteria, because of lack of upper motor neuron symptoms. However, pathological analysis of a muscle specimen showing neurogenic atrophy with type grouping might suggest the involvement of a chronic neurogenic process and are consistent with those of a previous cohort study involving patients with an ALS-like syndrome (12) . Several case reports have described spinal abnormalities detected with MRI scans in HAM/TSP patients (13) (14) (15) . Umehara et al (17) studied the cases of 11 patients who developed slowly progressive myelopathy associated with HTLV-I infection and who had abnormal spinal lesions as visualized by MRI. They classified the abnormal lesions into 3 types: those extending from the cervical to the thoracic level, those at the cervical level, and those at the thoracic level. Each type was associated with spinal swelling along with high intensity lesions, mainly located in the posterior columns, posterior horns, or lateral columns. Comparison of the clinical parameters, including the protein content, IgG level, and cell counts in the CSF of HAM/TSP patients with and without spinal lesions revealed that abnormal highintensity spinal lesions seen on T2-weighted images were reflective of active inflammation during the early stages of rapidly progressive HAM/TSP (16, 18) . In the present patient, fulminant myelopathy and abnormal spinal lesions detected by MRI may not be related to the early stages of HTLV-I-associated neurological manifestations. Umehara et al (19) reported two patients with HAM/TSP, who developed transient cervical cord lesions, as revealed by MRI, during the long-standing course of the illness. A possible explanation as to why upper motor neuron symptoms were absent in the patient might be the involvement of motor neuronopathy or proximal axonopathy, which is suggested by low frequency of F-wave production. Although the present case does not meet the diagnostic criteria for HAM/ TSP, the pathophysiology of the disease might be consistent with those of HAM/TSP as reported previously (19) .
Therapeutic trials on HAM/TSP patients have revealed the benefits of immunomodulatory therapy for this disease (20, 21) ; however, the beneficial effect of corticosteroid therapy for neurological manifestations apart from typical HAM/TSP is still debatable. Hanakawa et al (9) performed a trial on the use of corticosteroids in an HTLV-I carrier with an ALS-like manifestation. Within 3 weeks after oral prednisolone treatment, the patient's muscle strength on both sides improved, except in the severely affected small hand muscles. We treated the present patient with 2 cycles of highdose methylprednisolone followed by oral prednisolone.
Thereafter, the lightning pain and sensory disturbance, but not the muscle weakness and atrophy, partially improved. A possible explanation for these results is that corticosteroid therapy is more effective against acute symptoms such as lightning pain and sensory disturbances but less effective against chronic symptoms such as muscle weakness and atrophy.
The present case suggests that HTLV-I-infected individuals exhibit a wide variety of neurological manifestations apart from typical HAM/TSP. Of particular note is that fulminant myelopathy without upper motor neuron symptoms can occur years after the onset of neurogenic proximal muscular weakness associated with HTLV-I infection.
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